Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 12/20 | 0.38 |
| ▸ | ACACB | O00763 | 3/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4147516 | 0.92 | EPHX1 (0.46) | SRD5A2SMN1; SMN2FFAR4ACACBEPHX1 | |
| SCHEMBL4139878 | 0.92 | SMN1; SMN2 (0.43) | SRD5A2SMN1; SMN2FFAR4ACACB | |
| SCHEMBL4003108 | 0.92 | SMN1; SMN2 (0.43) | SRD5A2SMN1; SMN2FFAR4ACACB | |
| SCHEMBL4009711 | 0.92 | SRD5A2 (0.40) | SRD5A2SMN1; SMN2FFAR4ACACBEPHX1 | |
| SCHEMBL4153662 | 0.91 | SMN1; SMN2 (0.42) | SRD5A2SMN1; SMN2FFAR4ACACB | |
| SCHEMBL4004158 | 0.91 | SMN1; SMN2 (0.42) | SRD5A2SMN1; SMN2FFAR4ACACB | |
| SCHEMBL5950727 | 0.89 | GPR119 (0.42) | SRD5A2 | |
| SCHEMBL5950696 | 0.88 | ALDH1A1 (0.40) | SRD5A2SMN1; SMN2ACACB | |
| SCHEMBL4148781 | 0.84 | CNR1 (0.48) | SMN1; SMN2EPHX1 | |
| SCHEMBL5950205 | 0.82 | ACACB (0.39) | ACACBEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778229-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2009-06-17 | — | — | EP | claimed |
| EP-1778229-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-05-02 | — | — | EP | claimed |
| US-20060122197-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2006-06-08 | — | — | US | claimed |
| WO-2006020598-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-02-23 | — | — | WO | claimed |
| EP-1778229-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-1778229-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060122197-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2006-06-08 | — | — | US | disclosed |
| WO-2006020598-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122197-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | SRD5A2 19/4885SMN1; SMN2 3627/4885FFAR4 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.